First Horizon Advisors Inc. Reduces Holdings in Roche Holding AG (OTCMKTS:RHHBY)

First Horizon Advisors Inc. trimmed its holdings in shares of Roche Holding AG (OTCMKTS:RHHBY) by 23.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 970 shares of the company’s stock after selling 302 shares during the period. First Horizon Advisors Inc.’s holdings in Roche were worth $34,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of RHHBY. Kornitzer Capital Management Inc. KS increased its stake in shares of Roche by 1.3% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 136,923 shares of the company’s stock worth $5,490,000 after purchasing an additional 1,798 shares in the last quarter. Verity Asset Management Inc. purchased a new stake in Roche in the 3rd quarter worth approximately $253,000. Canopy Partners LLC grew its stake in Roche by 4.6% in the 3rd quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock worth $310,000 after acquiring an additional 344 shares during the period. Brooklyn Investment Group purchased a new stake in Roche in the 3rd quarter worth approximately $40,000. Finally, IHT Wealth Management LLC purchased a new stake in Roche in the 3rd quarter worth approximately $236,000.

Roche Trading Up 0.7 %

Shares of RHHBY opened at $41.74 on Friday. The company’s fifty day moving average is $38.24 and its two-hundred day moving average is $38.43. Roche Holding AG has a fifty-two week low of $29.20 and a fifty-two week high of $42.43. The company has a current ratio of 1.26, a quick ratio of 0.97 and a debt-to-equity ratio of 0.86.

Analyst Ratings Changes

Several research firms have commented on RHHBY. UBS Group raised shares of Roche from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Morgan Stanley began coverage on shares of Roche in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. Finally, Sanford C. Bernstein raised shares of Roche to a “strong-buy” rating in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Roche has an average rating of “Hold”.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.